Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Short Communication Volume 3 Issue 9

Gut Dysbiosis, Probiotics and COVID-19

Andrew P Smith*

Centre for Occupational and Health Psychology, School of Psychology, Cardiff University, UK

*Corresponding Author: Andrew P Smith, Centre for Occupational and Health Psychology, School of Psychology, Cardiff University, UK.

Received: July 30, 2020; Published: August 31, 2020

×

 The impact of COVID-19 is well documented, with over sixteen million people infected and 665,000 deaths [1]. With any infection it is necessary to consider countermeasures which can improve immune functioning and the immunological response to vaccination. Our bodies are host to large numbers of bacteria which colonise the skin and the digestive system. These organisms are referred to as microbiota and interest here lies in the gut microbiota. These show large individual variation [2], which may plausibly explain differences in susceptibility to and severity of disease. An abnormal gut microbiota is referred to as gut dysbiosis, and this has been shown to be a risk factor for disease. For example, hypertension is linked to gut dysbiosis [3], as is coronary heart disease [4]. Similarly, patients with both Type 1 [5] and Type 2 [6] diabetes show signs of gut dysbiosis. Susceptibility to, and the severity of COVID-19 has been shown to be associated with the same diseases that lead to gut dysbiosis. This suggests that one plausible method of preventing and managing COVID-19 might be by beneficial changes in the gut microbiota. This could involve the use of probiotics or possibly prebiotics that lead to positive changes in gut flora.

×

References

  1. “COVID-19 – Coronavirus pandemic”.
  2. Public Health England. “Disparities in the risk and outcomes of COVID-19”.
  3. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet10229 (2020): 1054-1062.
  4. Zhu Q., et al. “Dysbiosis signatures of gut microbiota in coronary artery disease”. Physiology Genomics10 (2018): 893-903.
  5. Zhou He., et al. “Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms”. Frontiers in Endocrinology 11 (2020): 125.
  6. Li X., et al. “Gut Microbiota Dysbiosis Drives and Implies Novel Therapeutic Strategies for Diabetes Mellitus and Related Metabolic Diseases”. Frontiers in Immunology 8 (2017): 1882.
  7. Thomas CM and Versalovic J. “Probiotics-host communication: modulation of signalling pathways in the intestine”. Gut Microbes 1 (2010): 148-163.
  8. Lomax A and Calder P. “Probiotics, immune function, infection and inflammation: a review of evidence from studies conducted in humans”. Current Pharmaceutical Design 15 (2009): 1428-1518.
  9. Maidens C., et al. “Modulation of vaccine response by concomitant probiotic administration”. British Journal of Clinical Pharmacology 75 (2013): 663-670.
  10. Llang T. “Handbook of COVID-19 prevention and treatment” (2020).
  11. Xu K., et al. “Management of coronavirus disease-19 (COVID-19): the Zhejiang experience”. Zheijiang Da Xue Bao Yi Xue Ban (2020): 49.
  12. Gao Y., et al. “2019 novel coronavirus infection and the gastrointestinal tract”. Journal of Digestive Disorders 21 (2020): 125-126.
  13. Calder P. “Nutrition, Immunity and COVID-19”. BMJ Nutrition, Prevention and Health 3 (2020): e000085.
  14. Gou W., et al. “Gut microbiota may underlie the predisposition of healthy individuals to COVID-19”. medRxiv (2020).
  15. D’Etorre., et al. “Challenges in the management of SARS-COV2 infection: the role of oral bacteriotherapy as complementary strategy to avoid the progression of COVID-19”. Frontiers in Medicine 7 (2020): 389.
  16. Enaud, R., et al. “The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks”. Frontiers in Cellular and Infection Microbiology 10 (2020): 9.
  17. Belojevic G and Prasher D. “Music of microbiota against SARS CoV2”. Noise and Health100 (2019): 97.
  18. Tannock, G. “Probiotics and Prebiotics: Scientific Aspects”. Norfolk (UK): Caister Academic Press (2005).
  19. Sonomoto, K., et al. “Lactic acid bacteria and bifidobacteria: Current progress in advanced research”. Norfolk (UK): Caister Academic Press (2011).
×

Citation

Citation: Andrew P Smith. “Gut Dysbiosis, Probiotics and COVID-19". Acta Scientific Gastrointestinal Disorders 3.9 (2020): 36-38.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor0.622

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US